Valproic acid (VPA) reduces sensorimotor gating deficits and HDAC2 overexpression in the MAM animal model of schizophrenia

Pharmacological Reports

Volumn 67, Issue 6, 2015, Pages 1124-1129

  Bator, Ewelina ^a   Latusz, Joachim ^a   Radaszkiewicz, Aleksandra ^a   Wedzony, Krzysztof ^a   MaćKowiak, Marzena ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Epigenetics; Medial prefrontal cortex; Sensorimotor gating; Valproic acid

Indexed keywords

HISTONE DEACETYLASE 2; HISTONE H3; METHYLAZOXYMETHANOL; VALPROIC ACID; HDAC2 PROTEIN, RAT; HISTONE; METHYLAZOXYMETHANOL ACETATE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HISTONE ACETYLATION; IMMUNOREACTIVITY; MEDIAL PREFRONTAL CORTEX; NONHUMAN; PRENATAL PERIOD; RAT; SCHIZOPHRENIA; SENSORY GATING; WESTERN BLOTTING; ACETYLATION; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PREFRONTAL CORTEX;

ACETYLATION; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HISTONE DEACETYLASE 2; HISTONES; MALE; METHYLAZOXYMETHANOL ACETATE; PREFRONTAL CORTEX; RATS; SCHIZOPHRENIA; SENSORY GATING; VALPROIC ACID;

EID: 84941236847     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2015.04.004     Document Type: Article

References (31)

1. L. Peixoto, and T. Abel The role of histone acetylation in memory formation and cognitive impairments Neuropsychopharmacology 38 1 2013 62 76
2. B. Tang, B. Dean, and E.A. Thomas Disease- and age-related changes in histone acetylation at gene promoters in psychiatric disorders Transl Psychiatry 1 2011 e64
3. R.P. Sharma, D.R. Grayson, and D.P. Gavin Histone deactylase 1 expression is increased in the prefrontal cortex of schizophrenia subjects: analysis of the National Brain Databank microarray collection Schizophr Res 98 1-3 2008 111 117
4. S. Bahari-Javan, A. Maddalena, C. Kerimoglu, J. Wittnam, T. Held, M. Bahr, and et al. HDAC1 regulates fear extinction in mice J Neurosci 32 15 2012 5062 5073
5. M. Kurita, T. Holloway, A. Garcia-Bea, A. Kozlenkov, A.K. Friedman, J.L. Moreno, and et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity Nat Neurosci 15 9 2012 1245 1254
6. M.J. Millan An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy Neuropharmacology 68 2013 2 82
7. T. Koseki, A. Mouri, T. Mamiya, Y. Aoyama, K. Toriumi, S. Suzuki, and et al. Exposure to enriched environments during adolescence prevents abnormal behaviours associated with histone deacetylation in phencyclidine-treated mice Int J Neuropsychopharmacol 15 10 2012 1489 1501
8. M. Mackowiak, E. Bator, J. Latusz, P. Mordalska, and K. Wedzony Prenatal MAM administration affects histone H3 methylation in postnatal life in the rat medial prefrontal cortex Eur Neuropsychopharmacol 24 2 2014 271 289
9. G.E. Kisby, H. Moore, and P.S. Spencer Animal models of brain maldevelopment induced by cycad plant genotoxins Birth Defects Res C: Embryo Today 99 4 2013 247 255
10. P. Flagstad, A. Mork, B.Y. Glenthoj, B.J. van, A.T. Michael-Titus, and M. Didriksen Disruption of neurogenesis on gestational day 17 in the rat causes behavioral changes relevant to positive and negative schizophrenia symptoms and alters amphetamine-induced dopamine release in nucleus accumbens Neuropsychopharmacology 29 11 2004 2052 2064
11. P. Flagstad, B.Y. Glenthoj, and M. Didriksen Cognitive deficits caused by late gestational disruption of neurogenesis in rats: a preclinical model of schizophrenia Neuropsychopharmacology 30 2 2005 250 260
12. G. Le Pen, R. Gourevitch, F. Hazane, C. Hoareau, T.M. Jay, and M.O. Krebs Peri-pubertal maturation after developmental disturbance: a model for psychosis onset in the rat Neuroscience 143 2 2006 395 405
13. H. Moore, J.D. Jentsch, M. Ghajarnia, M.A. Geyer, and A.A. Grace A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia Biol Psychiatry 60 3 2006 253 264
14. A.G. Kazantsev, and L.M. Thompson Therapeutic application of histone deacetylase inhibitors for central nervous system disorders Nat Rev Drug Discov 7 10 2008 854 868
15. M. Kilgore, C.A. Miller, D.M. Fass, K.M. Hennig, S.J. Haggarty, J.D. Sweatt, and et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease Neuropsychopharmacology 35 4 2010 870 880
16. C.J. Phiel, F. Zhang, E.Y. Huang, M.G. Guenther, M.A. Lazar, and P.S. Klein Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen J Biol Chem 276 39 2001 36734 36741
17. L. Tremolizzo, M.S. Doueiri, E. Dong, D.R. Grayson, J. Davis, G. Pinna, and et al. Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice Biol Psychiatry 57 5 2005 500 509
18. A. Guidotti, E. Dong, M. Kundakovic, R. Satta, D.R. Grayson, and E. Costa Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling Trends Pharmacol Sci 30 2 2009 55 60
19. N.R. Swerdlow, M. Weber, Y. Qu, G.A. Light, and D.L. Braff Realistic expectations of prepulse inhibition in translational models for schizophrenia research Psychopharmacology (Berl) 199 3 2008 331 388
20. J.C. Ong, S.A. Brody, C.H. Large, and M.A. Geyer An investigation of the efficacy of mood stabilizers in rodent models of prepulse inhibition J Pharmacol Exp Ther 315 3 2005 1163 1171
21. K. Umeda, K. Suemaru, N. Todo, N. Egashira, K. Mishima, K. Iwasaki, and et al. Effects of mood stabilizers on the disruption of prepulse inhibition induced by apomorphine or dizocilpine in mice Eur J Pharmacol 553 1-3 2006 157 162
22. M. Mackowiak, R. Guzik, D. Dudys, E. Bator, and K. Wedzony MK-801, a NMDA receptor antagonist, increases phosphorylation of histone H3 in the rat medial prefrontal cortex Pharmacol Rep 65 5 2013 1112 1123
23. D.E. Casey, D.G. Daniel, A.A. Wassef, K.A. Tracy, P. Wozniak, and K.W. Sommerville Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia Neuropsychopharmacology 28 1 2003 182 192
24. A.L. Larrison, S.L. Babin, Y. Xing, S.S. Patel, A.A. Wassef, and A.B. Sereno Effects of adjunct valproic acid on clinical symptoms and saccadic eye movements in schizophrenia Hum Psychopharmacol 26 7 2011 517 525
25. N.R. Swerdlow, M.A. Geyer, and D.L. Braff Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges Psychopharmacology (Berl) 156 2-3 2001 194 215
26. O.H. Kramer, P. Zhu, H.P. Ostendorff, M. Golebiewski, J. Tiefenbach, M.A. Peters, and et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2 EMBO J 22 13 2003 3411 3420
27. L. Tremolizzo, G. Carboni, W.B. Ruzicka, C.P. Mitchell, I. Sugaya, P. Tueting, and et al. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability Proc Natl Acad Sci U S A 99 26 2002 17095 17100
28. A. Guidotti, J. Auta, Y. Chen, J.M. Davis, E. Dong, D.P. Gavin, and et al. Epigenetic GABAergic targets in schizophrenia and bipolar disorder Neuropharmacology 60 7-8 2011 1007 1016
29. M. Haberland, R.L. Montgomery, and E.N. Olson The many roles of histone deacetylases in development and physiology: implications for disease and therapy Nat Rev Genet 10 1 2009 32 42
30. P.H. Huang, C.H. Chen, C.C. Chou, A.M. Sargeant, S.K. Kulp, C.M. Teng, and et al. Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases Mol Pharmacol 79 1 2011 197 206
31. H.S. Huang, A. Matevossian, C. Whittle, S.Y. Kim, A. Schumacher, S.P. Baker, and et al. Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters J Neurosci 27 42 2007 11254 11262